title: [Current status and future development of CAR-T gene therapy].
abstract: Adoptive T-cell therapy using chimeric antigen receptor (CAR) technology is a novel approach to cancer immuno-gene therapy. CARs are hybrid proteins consisting of a target-antigen-specific single-chain antibody fragment fused to intracellular T-cell activation domains (CD28 or CD137/CD3ζ receptor). CAR-expressing engineered T lymphocytes can directly recognize and kill tumor cells in an HLA independent manner. In the United States, promising results have been obtained in clinical trials of adoptive immuno-gene therapy using CD19-CAR-T lymphocytes for the treatment of refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and malignant lymphoma.
authors.affiliation: IMSUT Hospital.
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000009:adverse effects; D006801:Humans; D007938:Leukemia / Q000235:genetics / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins